乳腺放疗相关血管肉瘤与其他放疗相关肉瘤的结局及预后特征比较
该回顾性分析纳入176例局限性放疗相关肉瘤患者,其中乳腺放疗相关血管肉瘤67例(38%)、其他亚型109例(62%)。多因素分析显示切缘阳性、深部肿瘤位置和高分级与更差总生存相关;乳腺放疗相关血管肉瘤较其他放疗相关肉瘤初始放疗后潜伏期更短(8年 vs 15年,P<.001),3年无转移生存更高(82% vs 67%,P=.001),3年总生存呈更高趋势(84% vs 68%,P=.09)。
要点
- 切缘阴性、表浅位置和低分级是放疗相关肉瘤总生存改善的决定因素。
- 乳腺放疗相关血管肉瘤较其他放疗相关肉瘤潜伏期更短(8年 vs 15年,P<.001)。
- 乳腺放疗相关血管肉瘤3年无转移生存更高(82% vs 67%,P=.001),3年总生存呈更高趋势(84% vs 68%,P=.09)。
核心结论
- 切缘阴性切除、表浅肿瘤位置和低肿瘤分级是放疗相关肉瘤总生存改善的决定因素,提示完整手术切除在可能时是治疗的理想组成部分。
- 乳腺放疗相关血管肉瘤是临床病理学上独特的放疗相关肉瘤类型,初始放疗后潜伏期更短、复发模式不同,积极管理时与其他放疗相关肉瘤相比可能结局更好。
研究设计与样本
- 回顾性分析,纳入在机构多学科肉瘤门诊评估的176例局限性放疗相关肉瘤患者,进行临床与组织学复习以识别预后特征,部分病例行下一代测序分子分析。
主要发现
- 176例中组织学亚型包括血管肉瘤41%、未分化/未分类肉瘤40%、平滑肌肉瘤8%、恶性外周神经鞘瘤6%、骨肉瘤2%;乳腺放疗相关血管肉瘤67例(38%),其他放疗相关肉瘤109例(62%)。
- 治疗方式包括手术91%、化疗44%和放疗27%;中位随访3.2年,3年总生存为74%。
- 多因素分析显示切缘阳性(P<.0001)、深部肿瘤位置(胸腔内/腹腔内,P=.002)和高分级(P<.0001)与更差总生存相关;切缘阴性 vs 切缘阳性3年总生存为90% vs 66%。
- 乳腺放疗相关血管肉瘤 vs 其他放疗相关肉瘤:初始放疗后潜伏期8年 vs 15年(P<.001);3年总生存84% vs 68%(P=.09,呈更高趋势);3年无转移生存82% vs 67%(P=.001,显著更高);3年无局部复发生存54% vs 61%(P=.28,无显著差异)。
- 下一代测序发现总体低肿瘤突变负荷、乳腺放疗相关血管肉瘤中复发性MYC扩增,以及少数临床可操作的突变。
临床怎么用
- 作者认为切缘阴性切除、表浅肿瘤位置和低肿瘤分级是放疗相关肉瘤总生存改善的决定因素,提示完整手术切除在可能时是治疗的理想组成部分。
- 作者认为乳腺放疗相关血管肉瘤是临床病理学上独特的放疗相关肉瘤类型,积极管理时与其他放疗相关肉瘤相比可能结局更好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation-associated sarcomas (RAS) are considered to have a poor prognosis. Although the incidence is anticipated to rise, contemporary data regarding predictors of outcomes are few. We performed a retrospective analysis to identify RAS prognostic factors and subset analyses for radiation-associated angiosarcoma arising after treatment for breast cancer (RAAB) and other RAS subtypes (other-RAS). METHODS AND MATERIALS: Patients with localized RAS evaluated at an institutional multidisciplinary sarcoma clinic were identified. Clinical and histologic review was performed, and outcomes were assessed to identify prognostic features. A subset of cases underwent molecular analysis by next-generation sequencing. RESULTS: Among 176 patients, histologic subtypes of RAS included angiosarcoma (41%), undifferentiated/unclassified sarcoma (40%), leiomyosarcoma (8%), malignant peripheral nerve sheath tumor (6%), and osteosarcoma (2%). Sixty-seven patients (38%) had RAAB, and 109 (62%) had other-RAS. RAAB had significantly shorter latency from time of initial radiation compared with other-RAS (8 vs. 15 years; P < .001). Treatment approaches included surgery (91%), chemotherapy (44%), and radiation therapy (27%). Median follow-up was 3.2 years; 3-year overall survival (OS) was 74%. On multivariate analysis, positive margins (P < .0001), deep tumor location (intrathoracic/intra-abdominal, P = .002), and high grade (P < .0001) were associated with worse OS. In particular, 3-year OS with negative versus positive margins was 90% versus 66%. Patients with RAAB versus other-RAS showed a trend for higher 3-year OS (84% vs 68%; P = .09), significantly higher 3-year metastasis-free survival (82% vs 67%; P = .001), but similar 3-year local recurrence-free survival (54% vs 61%; P = .28). Next-generation sequencing identified overall low tumor mutational burden, recurrent MYC amplification in RAAB, and few clinically actionable mutations. CONCLUSIONS: Margin negative excision, superficial tumor location, and low tumor grade are determinants of improved OS for RAS, suggesting that complete surgical excision, when possible, is an optimal component of treatment. RAAB is a clinicopathologically distinct type of RAS with shorter latency from initial RT, different recurrence patterns, and when aggressively managed has potentially better outcomes compared with other-RAS.
引用
- Mito JK, Mitra D, Barysauskas CM, et al. A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas. Int J Radiat Oncol Biol Phys. 2019. PMID: 30703514. doi:10.1016/j.ijrobp.2019.01.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。